MDxHealth « Terug naar discussie overzicht

MDxHealth news 2012

467 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 ... 20 21 22 23 24 » | Laatste

Omlaag ↓

[verwijderd] 1 oktober 2012 17:06

Heb hem er bijna door nog een paar laatste stukjes

[verwijderd] 2 oktober 2012 10:24

Zo dichtbij! De beurs hersteld stevig! Zometeen schiet mdxh mee!

[verwijderd] 2 oktober 2012 12:21

Nog een paar stukjes en we zijn door de weerstand!

harrysnel 2 oktober 2012 15:03

Artikel over MDXHealth op Bloomberg:

Prostate-Cancer Test May Reduce Repeat Biopsies: Study

By Makiko Kitamura - Oct 2, 2012 10:58 AM GMT+0200

A new gene-based test for prostate cancer may reduce the need to repeat painful biopsies that can also cause serious infections, according to a study to be published in the Journal of Urology.

The ConfirmMDx test, sold by MDxHealth SA (MDXH) and based on technology developed at Johns Hopkins University, examined samples from biopsies and confirmed whether a patient was clear of cancer with 90 percent accuracy, according to the study of 498 men who underwent a second biopsy within 30 months. The findings will appear in the November issue of the journal, according to the Liege, Belgium-based company.

The results’ publication should help attract the attention of physicians and drive both revenue and reimbursement from health insurers, said Rudi Marien, managing director of Biovest NV, which holds 15 percent of MDxHealth shares. Sales began in May and are so far in line with company expectations, Chief Executive Officer Jan Groen said in an interview. At least a quarter of negative biopsy results are false negatives, prompting patients to repeat the sometimes risky procedure.

“It’s not a small thing to subject a patient to a second biopsy,” said Eric Wallen, a professor of urology at the University of North Carolina who began using the test three months ago. With a negative result from ConfirmMDx, “I can reassure patients that I’ve got a test here that tells me I can be quite confident that there isn’t a cancer hiding that I missed.”

MDxHealth shares have gained 34 percent this year. The Belgian company funded the study.

Infection Risk

About 1.5 million men get abnormal results from so-called PSA tests annually in the U.S., leading to more than 900,000 biopsies a year, according to Michael King, an analyst at Nomura Code Securities Ltd. in London. The procedure involves passing a needle through the rectum and into the prostate gland to take eight to 12 tissue samples.

About one in 200 men who undergo a prostate biopsy will develop a serious infection or report trouble urinating, researchers said in a scientific review published last year in the Annals of Internal Medicine. The 15-minute test carries an infection risk because the needle can take bacteria from the bowel into the prostate, bladder and bloodstream.

MDxHealth’s test analyzes biopsy samples to determine whether some genes such as those that suppress tumors are switched off, a process that’s associated with the presence or development of most cancers.

‘Convince Urologists’

The product will compete with a test from Mitomics Inc., which the Thunder Bay, Ontario-based company says can rule out cancer with 91 percent accuracy. Epigenomics AG, based in Berlin, uses a similar approach in tests to detect colon and lung cancers, which are marketed in Europe. A colon cancer test awaits U.S. regulatory approval.

ConfirmMDx may help insurers save money by cutting the number of unnecessary biopsies, according to CEO Groen. The procedure costs about $2,500, whereas Nomura Code’s King estimates the price of the test at about $146 per tissue sample. MDxHealth says it is only targeting urologists in the U.S., given the size of the market and the fact that European countries each have distinct procedures for reimbursement.

MDxHealth has also partnered with drugmakers such as GlaxoSmithKline Plc of London and Whitehouse Station, New Jersey-based Merck & Co. on diagnostics that help determine whether patients respond to the companies’ cancer treatments.

Sales of those tests and the introduction of ConfirmMDx pushed up sales 43 percent to 2.01 million euros ($2.59 million) in the six months ended June 30. MDxHealth may report a profit in 2014, according to Nomura Code.

The company says it’s also developing a version of ConfirmMDx for lung cancer. A second test in the works could help distinguish between aggressive and slow-growth cancers.

“MDxHealth’s diagnostic technology has the potential to be used in a wide number of cancer applications,” Nomura’s King said. “The publication will certainly help the company convince urologists.”

www.bloomberg.com/news/2012-10-02/pro...

[verwijderd] 2 oktober 2012 16:08

ow nice!

[verwijderd] 2 oktober 2012 16:16

harry heb jij nog een belang in mdxh?

harrysnel 2 oktober 2012 16:56

quote:
Debit or Credit schreef op 2 oktober 2012 16:16:
harry heb jij nog een belang in mdxh?

Heb idd weer aandelen in portefeuille. Onlangs nog wat bijgekocht mede omdat Rudi Mariën na bod op Devgen binnenkort weer veel geld beschikbaar heeft:)..

[verwijderd] 2 oktober 2012 16:59

quote:
harrysnel schreef op 2 oktober 2012 16:56:
[...]

Heb idd weer aandelen in portefeuille. Onlangs nog wat bijgekocht mede omdat Rudi Mariën na bod op Devgen binnenkort weer veel geld beschikbaar heeft:)..

Ik heb ook nog flink aan die 1,92 geknabbeld. Als hij daar stevig doorheen schiet kan het hard gaan als we door de 2-. schieten!

[verwijderd] 3 oktober 2012 14:52

en er ligt weer goedkoop spul voor het oprapen!

[verwijderd] 3 oktober 2012 15:02

die 1,92 moet vallen vandaag!

[verwijderd] 4 oktober 2012 11:39

Goed bijgekocht afgelopen dagen. 1,92 omslagpunt. Kooptrigger van 20k op 1,95 geplaats.

[verwijderd] 5 oktober 2012 12:03

Vandaag moet het gebeuren!

[verwijderd] 5 oktober 2012 16:11

quote:
Debit or Credit schreef:
Goed bijgekocht afgelopen dagen. 1,92 omslagpunt. Kooptrigger van 20k op 1,95 geplaats.

Lijkt erop alsof je het hele forum voor jezelf hebt, blijf vooral bijkopen

[verwijderd] 8 oktober 2012 09:44

FOR IMMEDIATE RELEASE
Media Contact:
Edwin Hendrick
(949)542-3990
ehendrick@plusdx.com
PLUS DIAGNOSTICS® LAUNCHES NEW REPORTING APP
FOR SMARTPHONES AND TABLETS
Irvine, CA – October 5, 2012 – PLUS Diagnostics, a leading anatomic pathology company,
announced today that it has launched a new reporting application, PLUSDx Mobile™, for
smartphones and tablets that allows physicians easy, remote access to their patients’ reports.
With PLUSDx Mobile, pathology reports are delivered to a handheld device immediately
following pathologist sign out. The app also offers many convenient features to physicians such
as the ability to add notes to a case or mark the case for follow-up. A customizable date range
allows reports to be saved to the device and a simple “Search” feature quickly locates results for
a specific patient. The PLUSDx Mobile app is currently available for iPad and iPhone devices,
with the app and support for Android-based smartphones and tablets following shortly.
“PLUS Diagnostics is dedicated to providing our customers and their patients with the highest
quality of care and technology. We are excited to offer physicians the next level of efficiency and
convenience with remote access to their patients reports via their handheld device.
PLUSDx Mobile is logical and user-friendly yet provides an innovative solution to meet our
customers evolving needs,” said David Pauluzzi, Chief Executive Officer, PLUS Diagnostics.
About PLUS Diagnostics
PLUS Diagnostics is a leading national pathology company that provides a full range of multispecialty
services, including extensive diagnostic procedures and specialist consultations.
Accredited by the College of American Pathologists, PLUS Diagnostics has long been
recognized for exceptional service and quality. The company currently focuses on a broad base
of specialty pathology services, including urology, gastroenterology and hematology/oncology.
PLUS Diagnostics is a company of Water Street Healthcare Partners. For more information,
visit, www.plusdx.com.

[verwijderd] 9 oktober 2012 18:04

Gesloten op YH met hoger dan normaal volume. Technische weerstanden korte en middellange termijn doorbroken.

[verwijderd] 9 oktober 2012 19:16

quote:
hugbu schreef op 9 oktober 2012 18:04:
Gesloten op YH met hoger dan normaal volume. Technische weerstanden korte en middellange termijn doorbroken.

Ja, daarom morgen weer kopen!!

[verwijderd] 10 oktober 2012 09:47

is er nieuws? Een freeze@! wat een volume!

[verwijderd] 10 oktober 2012 09:47

KOPEN!!! NU!!!!

[verwijderd] 10 oktober 2012 10:02

15K erbij

[verwijderd] 10 oktober 2012 10:03

koersdoel is 3,75 van amerikaanse analist

467 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 ... 20 21 22 23 24 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	1 jan 0001
Koers	0,000
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	0

nieuws meer

11:12	Beursupdate: AEX zet opmars voort ond...
10:35	Von der Leyen verwerpt Amerikaanse im...
10:00	Must read: Grondstoffensector heeft w...
09:51	Beursblik: DSM incasseert sterke verk...
09:50	KBC Securities haalt NX Filtration va...
09:15	AEX nipt hoger van start gegaan onder...
09:03	Omzet en winst Kering flink onder druk
08:52	Fors lagere winst voor BP
08:43	UniCredit voorziet lagere rentebaten ...
08:25	Meer winst voor Rabobank